Tg Therapeutics (TGTX) Deferred Taxes (2025 - 2026)

Tg Therapeutics (TGTX) recorded quarterly Deferred Taxes of $3.9 million in Q1 2026, down 79.26% quarter-over-quarter from $18.6 million in Q4 2025.

Tg Therapeutics (TGTX) Deferred Taxes (2025 - 2026) Analysis & Trends

Tg Therapeutics' Deferred Taxes history runs 2 years deep, the most recent figure standing at $3.9 million for Q1 2026.

  • In Q1 2026, Deferred Taxes changed N/A year-over-year to $3.9 million; the TTM figure through Mar 2026 stood at $22.5 million (changed N/A YoY), while the FY2025 annual figure was -$348.0 million, changed N/A from the prior year.
  • Deferred Taxes was $3.9 million for Q1 2026 at Tg Therapeutics, down from $18.6 million in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $18.6 million in Q4 2025 to a low of $3.9 million in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Deferred Taxes (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -859,000.00
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -65.30 Mn
9 Abivax 91.96 Bn 91.96 Bn - -
10 Tg Therapeutics 7.71 Bn 7.06 Bn 171.41 Mn 3.86 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 3.86 Mn
Dec 31, 2025 18.63 Mn